TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:45
Alzamend Neuro Inc. ( ALZN ) https://www.alzamend.com
1.24USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-86.07%
ALZN
SPY
32.66%
-99.62%
ALZN
SPY
108.59%
ALZN
0.00%
SPY
302.52%
ALZN
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
4.06
-0.03
0.10
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.69
53.36
1.08
-638.16
0.00
0.01
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-1264.49
-16.67
-1470.85
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-275.01
-321.67
0.00
Other Earnings and Cash Flow Stats:
Alzamend Neuro Inc. ( ALZN ) Net Income TTM ($MM) is -5.90
Alzamend Neuro Inc. ( ALZN ) Operating Income TTM ($MM) is -5.83
Alzamend Neuro Inc. ( ALZN ) Owners' Earnings Annual ($MM) is 0.00
Alzamend Neuro Inc. ( ALZN ) Current Price to Owners' Earnings ratio is 0.00
Alzamend Neuro Inc. ( ALZN ) EBITDA TTM ($MM) is -5.78
Alzamend Neuro Inc. ( ALZN ) EBITDA Margin is -1470.85%
Capital Allocation:
Alzamend Neuro Inc. ( ALZN ) has paid 0.00 dividends per share and bought back -2.875324 million shares in the past 12 months
Alzamend Neuro Inc. ( ALZN ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Alzamend Neuro Inc. ( ALZN ) Interest-bearing Debt ($MM) as of last quarter is 0
Alzamend Neuro Inc. ( ALZN ) Annual Working Capital Investments ($MM) are 3
Alzamend Neuro Inc. ( ALZN ) Book Value ($MM) as of last quarter is 3
Alzamend Neuro Inc. ( ALZN ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Alzamend Neuro Inc. ( ALZN ) has 4 million in cash on hand as of last quarter
Alzamend Neuro Inc. ( ALZN ) has 1 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Alzamend Neuro Inc. ( ALZN ) has 3 common shares outstanding as of last quarter
Alzamend Neuro Inc. ( ALZN ) has 0 million USD of preferred stock value
Academic Scores:
Alzamend Neuro Inc. ( ALZN ) Altman Z-Score is -15.91 as of last quarter
Alzamend Neuro Inc. ( ALZN ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Alzamend Neuro Inc. ( ALZN ) largest shareholder is owning shares at 0.00 ($MM) value
AULT MILTON C III(an insider) Bought 75 shares of Alzamend Neuro Inc. ( ALZN ) for the amount of $206.25 on 2024-08-06
4.55% of Alzamend Neuro Inc. ( ALZN ) is held by insiders, and 0.94% is held by institutions
Alzamend Neuro Inc. ( ALZN ) went public on 2021-06-15
Other Alzamend Neuro Inc. ( ALZN ) financial metrics:
FCF:-8.39
Unlevered Free Cash Flow:0.00
EPS:-1.60
Operating Margin:-1264.49
Gross Profit Margin:-16.67
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-150.84
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Alzamend Neuro Inc. ( ALZN ) :
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.